Skip to main content
OpenTrials
Completed

NCT Number: NCT02968498

Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers

Prospective, open, mono-center, randomized, two part study with 4-way cross-over design in each study part.

The objective of the study is to investigate blood glucose levels after oral intake of defined amounts of lactulose.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CRO BioTeSys GmbH

Esslingen am Neckar, 73728, Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteers
  • Age: 18-65 years
  • Approx. 3-5 bowel movements per week
  • Caucasian
  • Availability and presence in the trial unit for approx. 4 hours/ week for 4 times in a row with approx. 1 week of washout in between
  • Signed informed consent form

Exclusion criteria

  • Known (family) history of diabetes mellitus or use of anti-hyperglycaemic drugs or Insulin
  • Clinically relevant renal or hepatic disease, liver enzymes > 10% above reference range
  • Fasting blood glucose > 100 mg/dL or HbA1c outside of reference range
  • Total cholesterol > 250 mg/dL or triglycerides > 150 mg/dL
  • Haemoglobin < 11 g/dL (women); < 12.5 g/dL (men)
  • BMI < 19 kg/m² and ≥ 30 kg/m²
  • Intentional and unintentional weight loss > 5% in the previous 6 months
  • Smoker
  • Major medical or surgical event requiring hospitalization within the previous 3 months
  • Presence of disease or drug(s) influencing digestion and absorption of nutrients or bowel habits
  • Intake of medications known to affect glucose tolerance, e.g., steroids, protease inhibitors or antipsychotics (stable doses of e.g., oral contraceptives, thyroxin, vitamins and mineral supplements or drugs to treat hypertension or osteoporosis are acceptable)
  • Chronic intake of substances affecting blood coagulation (e.g. acetylic acid, anticoagulants, diuretics, thiazides), which in the investigator's opinion would impact volunteer safety
  • Hereditary problems of galactose or fructose intolerance, lactase deficiency or glucose-galactose malabsorption
  • Suspicion of drug abuse
  • Abuse of alcoholic drinks, defined as an average daily intake of more than one litre of beer per day or equivalent amount of alcohol in other beverages
  • Pregnant or breast feeding women
  • Known or suspected allergy to any component of the investigational product(s)
  • Known HIV-infection
  • Known acute or chronic hepatitis B and C infection
  • Blood donation within 4 weeks prior to visit 1 or during the study
  • Volunteer unable to co-operate adequately
  • Participation in a clinical trial with an investigational product within one month before start of study

Treatment and study plan

Lactulose crystals 10 g

Dietary Supplement

White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.

Lactulose crystals 20 g

Dietary Supplement

White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.

Lactulose liquid 10 g

Dietary Supplement

Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.

Lactulose liquid 20 g

Dietary Supplement

Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.

Oral glucose 20 g

Dietary Supplement

White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.

Other names: glucose monohydrate

Still water

Dietary Supplement

Still water will be used. Water from the same source will be also used to dissolve investigational and control products.

Primary outcomes

  1. Capillary blood glucose levels as incremental area under the curve (iAUC) above baseline (iAUC(0-180min))

    Time frame: 0-180 min

Secondary outcomes

  1. Maximum blood glucose concentration (Cmax)

    Time frame: 0-180 min

  2. Maximum increase of blood glucose concentration (Max_increase)

    Time frame: 0-180 min

    Cmax minus baseline value

  3. Relative maximum increase of blood glucose concentration(Max_increase rel)

    Time frame: 0-180 min

    Cmax / baseline value

  4. Time to reach maximum blood glucose concentration (Tmax)

    Time frame: 0-180 min

  5. First time to reach baseline again after increase or decrease in blood glucose (Tbaseline)

    Time frame: 0-180 min

  6. Total area under curve from 0 to 180 min for blood glucose concentration (AUC(0-180min))

    Time frame: 0-180 min

  7. Baseline corrected area under curve from 0 to 180 min for blood glucose concentration (AUCbase_c(0-180min))

    Time frame: 0-180 min

    Area under curve from 0 to 180 min minus baseline*180min

  8. Adverse events (AEs)

    Time frame: After screening till study day 22 (+24 hours)

  9. Gastrointestinal tolerability (assessed by subject's questionnaire)

    Time frame: 180 min

  10. Gastrointestinal tolerability (assessed by subject's questionnaire)

    Time frame: 24 hours post-dose

Sponsors and collaborators

Lead sponsor

Fresenius Kabi

Industry

Registry information

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Nov 18, 2016
Registry last updated
Mar 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.